drugset / Trial / NCT03097107
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.
Timeline
- Start
- 2017-04-06
- Primary completion
- 2023-12
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saroglitazar | Small molecule | 1 mg | Oral |
| Subject | Saroglitazar | Small molecule | 2 mg | Oral |
| Subject | Saroglitazar | Small molecule | 4 mg | Oral |